TY - JOUR
T1 - Antiviral T Cells for Adenovirus in the Pretransplant Period
T2 - A Bridge Therapy for Severe Combined Immunodeficiency
AU - Miller, Holly K.
AU - Hanley, Patrick J.
AU - Lang, Haili
AU - Lazarski, Christopher A.
AU - Chorvinsky, Elizabeth A.
AU - McCormack, Sarah
AU - Roesch, Lauren
AU - Albihani, Shuroug
AU - Dean, Marcus
AU - Hoq, Fahmida
AU - Adams, Roberta H.
AU - Bollard, Catherine M.
AU - Keller, Michael D.
N1 - Funding Information:
Financial disclosure: This work was supported by funding from the Jeffrey Modell Foundation, and a grant from the National Heart, Lung, and Blood Institute (K23-HL136783-01 to MDK).
Publisher Copyright:
© 2018 The American Society for Blood and Marrow Transplantation
PY - 2018/9
Y1 - 2018/9
N2 - Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Adenovirus cleared following 2 doses of VSTs and marrow infusion from a matched unrelated donor, without incidence of graft versus host disease. T cell receptor-b sequencing demonstrated expansion of adenovirus-specific T cell fraction of the VSTs, suggesting that infusion facilitated viral clearance. This report suggests that VSTs are likely safe in the pre-HSCT period, and may be a useful bridge therapy for infants with SCID and persistent viral infections.
AB - Viral infections can be life threatening in patients with severe combined immunodeficiency (SCID) and other forms of profound primary immunodeficiency disorders both before and after hematopoietic stem cell transplantation (HSCT). Adoptive immunotherapy with virus-specific T cells (VSTs) has been utilized in many patients in the setting of HSCT, but has very rarely been attempted for treatment of viral infections before HSCT. Here we describe the use of VSTs in an infant with RAG1 SCID who had developed disseminated adenovirus which failed to improve on cidofovir. Adenovirus cleared following 2 doses of VSTs and marrow infusion from a matched unrelated donor, without incidence of graft versus host disease. T cell receptor-b sequencing demonstrated expansion of adenovirus-specific T cell fraction of the VSTs, suggesting that infusion facilitated viral clearance. This report suggests that VSTs are likely safe in the pre-HSCT period, and may be a useful bridge therapy for infants with SCID and persistent viral infections.
KW - Adenovirus
KW - Adoptive immunotherapy
KW - Severe combined immunodeficiency
KW - T-lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=85047327444&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047327444&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2018.04.030
DO - 10.1016/j.bbmt.2018.04.030
M3 - Article
AN - SCOPUS:85047327444
SN - 1083-8791
VL - 24
SP - 1944
EP - 1946
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 9
ER -